Drug details

Praluent (alirocumab for solution for subcutaneous injection)

type of PCSK9 Inhibitors

Praluent (alirocumab) injection is a PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) inhibitor antibody indicated as adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL-cholesterol (LDL-C).

This drug may have the following side effects:

• diarrhea,
• cough,
• allergic reactions, and
• urinary tract infection,
• sinus infection,
• bruising, 
• muscle pain or spasms,
• bronchitis,
• influenza,
• sore throat and runny or stuffy nose (nasopharyngitis),
• injection site reactions (swelling, pain, itching, redness, tenderness),
  
• elevated liver enzymes.

The following drugs are related to Praluent, either as a replacement or used together:

• Crestor (rosuvastatin calcium)
• Evkeeza (evinacumab-dgn for injection)
• Repatha (evolocumab injection, for subcutaneous injection)
• Zetia (ezetimibe tablets)
• Trilipix (fenofibric acid capsules)
• Leqvio (inclisiran injection)
• Mevacor (lovastatin)
• Lovaza (omega-3-acid ethyl esters)
• Vayarol (orally administered prescription medical food)
• Pravachol (pravastatin sodium)
• Rosuvastatin Calcium Tablets (rosuvastatin calcium)
• Simcor (simvastatin niacin extended release)
• Zocor (simvastatin)